ENDPOINTS

Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter

Sanofi is buying a B cell-depleting antibody developed by Dren Bio as a therapy for cancer and autoimmune diseases. The pharma said on Thursday that it will pay $600 million in ...

Mar 20, 2025 - 11:50
 0
Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter
Sanofi is buying a B cell-depleting antibody developed by Dren Bio as a therapy for cancer and autoimmune diseases. The pharma said on Thursday that it will pay $600 million in ...
Read More

Tags:

Previous Article

Daily briefing: About 1% of children have genetic paternity other than that reco...

Next Article

Meta: Open Store & Worlds Push Didn't Affect Spending, Headset Usage Up 30%

Related Posts

Inventiva cuts pipeline, halves staff in bid to get to Phase 3 MASH readout

Inventiva cuts pipeline, halves staff in bid to get to ...

Feb 11, 2025  0

Ginkgo uncertain over the future of US government funding, stock drops

Ginkgo uncertain over the future of US government fundi...

Feb 26, 2025  0

In single case, spinal muscular atrophy pill given before birth spared baby of symptoms

In single case, spinal muscular atrophy pill given befo...

Feb 20, 2025  0